| Alexion Posts a Strong Quarter on Renewed Sales Zacks.com submits: Alexion Pharmaceuticals (ALXN) reported first quarter of fiscal 2010 earnings per share of 23 cents, well above 16 cents in the year-ago quarter. However, excluding a non-cash tax expense, the company’s EPS came in at 29 cents, surpassing the Zacks Consensus Estimate by 6 cents.Alexion’s revenues increased 44.5% to $117.6 million from $81.3 million in the year-ago quarter driven by strong Soliris (eculizumab) sales. Soliris posted robust sales primarily due to the addition of a significant number of new patients in both the US and Europe.Complete Story » seekingalpha.com |
Families Hear Gene Secrets Children's Hospital Boston has designed a new genetic research project so information gleaned from DNA can benefit not only science, but potentially participants themselves. online.wsj.com |
Skilled Healthcare Faces Over $671 Million in Damages Skilled Healthcare faces payments of over $671 million in damages awarded by a California jury in a lawsuit over alleged violations at 22 of its nursing facilities. online.wsj.com |
New Facility Won't Use St. Vincent's Site North Shore-Long Island Jewish Health System will open an urgent care-center on West 20th Street, after the hospital failed to reach an agreement to house services in the bankrupt St. Vincent's Hospital. online.wsj.com |
Biotechs With Room to Run M.E. Garza submits: Here now is our opportunity to reiterate some of the solid companies that we've covered recently- especially since they have treated our readers and investors well. It's important to note that some of these runners are still not done, so keep a close eye because there is definitely more to come. Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) - This stock has been on fire since their $18M direct offering back in August, up roughly 40% since the lows in August. This stock still has more room to climb up until their PDUFA date for AZ-004 on October 11th, 2010. See our original report for all the detailsCleveland BioLabs, Inc. (NASDAQ:CBLI) - Shares of CBLI have been climbing since we said that the company was in line for some substantial government contracts. The stock was trading at $3.81at the time but it saw a high of $5.75 on Friday after the company was awarded a $45 million contract (including options), from the United States Department of Defense (DoD) Chemical Biological and Medical Systems (CBMS) - Medical Identification and Treatment Systems (MITS) to develop and stockpile their CBLB502 drug as a medical radiation countermeasure.Complete Story » seekingalpha.com |